Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.61 |
| ▸ | PARG | Q86W56 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2765028 | 1.00 | ADAMTS5 (0.61) | ADAMTS5PARGKMT2AMAPTMEN1 | |
| SCHEMBL5495290 | 1.00 | ADAMTS5 (0.61) | ADAMTS5PARGKMT2AMAPTMEN1 | |
| SCHEMBL2766469 | 0.84 | ADAMTS5 (0.59) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2766471 | 0.84 | ADAMTS5 (0.59) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2764179 | 0.80 | ADAMTS5 (0.86) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2764182 | 0.80 | ADAMTS5 (0.86) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2765817 | 0.79 | ADAMTS5 (0.56) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2764552 | 0.79 | ADAMTS5 (0.56) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL2766620 | 0.79 | ADAMTS5 (0.68) | ADAMTS5KMT2AMAPTMEN1MAPK1 | |
| SCHEMBL5492553 | 0.79 | ADAMTS5 (0.56) | ADAMTS5KMT2AMAPTMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | claimed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | claimed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | claimed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1694410-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885PARG 4625/4885KMT2A 3146/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | ADAMTS5 38/4885PARG 4601/4885KMT2A 3165/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885PARG 4601/4885KMT2A 3165/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885PARG 4575/4885KMT2A 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.